Page 2 – Pork Checkoff

Pork Checkoff Research

Research is at the heart of the National Pork Board’s mission and is funded by your Pork Checkoff dollars. Research is administered in all areas of pork production, processing, and human nutrition to develop a higher quality and more profitable product in the competitive meat protein market.

Contribute to Pork Research

Learn more about how you can help advance the pork industry through ongoing research.

Swine Health - Foreign Animal Disease
Animal welfare implications resulting from movement restriction for foreign animal disease outbreak management in the pork industry
Trends in the U.S. swine industry show that over the years, there has been an increase in improved producer efficacy and the appearance of fewer but larger pig farms. These changes are reflected...
Swine Health - PRRS
Development of next generation sequencing methodology for full genome characterization of porcine reproductive and respiratory syndrome virus (PRRSV) from oral fluids and nasal swabs
Porcine reproductive and respiratory syndrome virus (PRRSV) is one of the most significant swine diseases with near worldwide distribution. In the U.S., open reading frame 5 (ORF5) is commonly...
Swine Health - General Disease
Evaluation of diagnostic performance characteristics of commercially-available CSFV tests
Classical swine fever virus (CSFV) is endemic and circulates in many regions of the world; therefore, the potential re-emergence of CSFV is a continual risk. It is in the pork producers' best...
Swine Health - Foreign Animal Disease
Disinfection of foreign animal disease viruses on surfaces relevant to the Pork Packing Industry
The overall purpose of this research was to test the efficacy of commercial chemical disinfectants against foreign animal disease (FAD) viruses dried in swine products and on surfaces relevant...
Swine Health
Development of a CSFV Erns IgG AlphaLISA® assay capable of differentiating infected from CSFV-vaccinated animals (DIVA)

Study aimed to develop a CSFV Erns IgG AlphaLISA® for serum and oral fluids that would complement currently available CSFV E2 DIVA vaccines.

Sort and Filter
  • Sort and Filter By

  • Category

  • Institution

  • Funded By